Arbutus Biopharma (ABUS) Return on Sales (2016 - 2025)
Historic Return on Sales for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to 14.61%.
- Arbutus Biopharma's Return on Sales rose 1200.0% to 14.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.89%, marking a year-over-year increase of 84800.0%. This contributed to the annual value of 11.33% for FY2024, which is 73100.0% down from last year.
- Per Arbutus Biopharma's latest filing, its Return on Sales stood at 14.61% for Q3 2025, which was up 1200.0% from 0.23% recorded in Q2 2025.
- Arbutus Biopharma's 5-year Return on Sales high stood at 0.23% for Q2 2025, and its period low was 14.73% during Q3 2024.
- Over the past 5 years, Arbutus Biopharma's median Return on Sales value was 6.65% (recorded in 2021), while the average stood at 6.88%.
- In the last 5 years, Arbutus Biopharma's Return on Sales plummeted by -104100bps in 2024 and then surged by 117000bps in 2025.
- Arbutus Biopharma's Return on Sales (Quarter) stood at 6.65% in 2021, then soared by 47bps to 3.51% in 2022, then crashed by -156bps to 9.0% in 2023, then grew by 12bps to 7.94% in 2024, then plummeted by -84bps to 14.61% in 2025.
- Its last three reported values are 14.61% in Q3 2025, 0.23% for Q2 2025, and 13.91% during Q1 2025.